Any of these warrant staying at the current dose for 2 to 4 additional weeks before attempting the next increase
Half-life ~30 min plasma half-life reported in rat models (subcutaneous administration)
Abbott India Limited manufactures Extensior 0.25 mg Injection at GMP-compliant facilities, adhering to strict quality standards
Several large-scale cardiovascular outcome trials (including LEADER, SUSTAIN-6, and REWIND) have shown that certain GLP-1 receptor agonists liraglutide, semaglutide, and dulaglutide reduce the risk of major adverse cardiovascular events such as heart attack, stroke, and cardiovascular death in people with established cardiovascular disease or multiple cardiovascular risk factors
Importantly, exendin-4 reduced GLP-1R overexpression in sensitized bronchi, suggesting a feedback mechanism that regulates receptor activation and prevents overstimulation